# 5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors

> **NCT07404332** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Mohammed Milhem** · enrollment: 35 (estimated)

## Conditions studied

- Solid Tumor
- Locally Advanced Solid Tumor
- Metastatic Tumor

## Interventions

- **DRUG:** 5 Azacytidine
- **DRUG:** Pembrolizumab
- **DRUG:** Nivolumab
- **DRUG:** Cemiplimab

## Key facts

- **NCT ID:** NCT07404332
- **Lead sponsor:** Mohammed Milhem
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02-28
- **Primary completion:** 2028-02-28
- **Final completion:** 2031-02-28
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2026-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07404332

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07404332, "5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07404332. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*